Table 1.

Baseline characteristics of patients randomized to SOC or SOC plus IO, and patients assigned to SOC plus IO on the safety lead-in arm.

Characteristic		Number (%)
		Standard of care (n = 10)	Standard of care + IO (n = 10)	Lead-In (n = 6)
Gender	Female	7 (70%)	4 (40%)	1 (16.7%)
	Male	3 (30%)	6 (60%)	5 (83.3%)
Primary tumor location	Left	6 (60%)	8 (80%)	3 (50%)
	Right	4 (40%)	2 (20%)	3 (50%)
Prior adjuvant therapy	Yes	4 (40%)	1 (10%)	0
	No	6 (60%)	9 (90%)	6 (100%)
RAS Status	Wild Type	3 (30%)	7 (70%)	2 (33.3%)
	Mutant	7 (70%)	2 (20%)	2 (33.3%)
	Unknown	0	1 (10%)	2 (33.3%)
BRAF V600E Status	Wild Type	10 (100%)	8 (80%)	3 (50%)
	Mutant	0	2 (20%)	1 (16.7%)
	Unknown	0	0	2 (33.3%)

Abbreviations: IO, immuno-oncology.